Showing 1341-1350 of 9427 results for "".
DermWireTV: Cosentyx for Kids; Anifrolumab for SLE, Tremfya in PsA at EULAR
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-for-kids-anifrolumab-for-sle-tremfya-in-psa-at-eular/19948/FDA has approved Cosentyx (secukinumab) from Novartis for patients as young as six years old. The 2nd Annual San Diego Dermatology Symposium kicks off as a live Virtual Experience next Friday. A post-hoc analysis of pooled data from the TULIP Phase 3 clinical trials shows that anifrolumab improvesNew SEO Trends Dermatologists Should Anticipate in 2021
https://practicaldermatology.com/topics/practice-management/new-seo-trends-dermatologists-should-anticipate-in-2021/19900/Dermatology online marketing will have a surge of possible business in 2021 as people start moving back to requesting and seeking medical care again, especially once COVID-19 vaccines become widespread. Getting ahead of the SEO search curve now will give your office the advantage before the demand mDermWireTV: Zilxi Launch, Eczema Awareness, Uninsurance Rates
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-zilxi-launch-eczema-awareness-uninsurance-rates/19863/For eczema awareness month, the National Eczema Association (NEA) is offering virtual educational programs, community engagement activities, and additional free resources. Georgia, Oklahoma, and Texas have the highest rates of uninsurance. Zilxi minocycline topical foam launches as new data fromDERM2020 Exhibitor Reaction: Sam Widdicombe, Almirall
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-exhibitor-reaction-sam-widdicombe-almirall/19843/Sam Widdicombe of Almirall, a DERM2020 exhibitor, tells us what she thinks of the conference and has a few positive messages for her team.DermWireTV: Enbrel/AD Link, LGBTQ Health and Dermatology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-enbrelad-link-lgbtq-health-and-dermatology/19624/Signals in accumulated data for Enbrel seem to suggest that etanercept may have a protective effect against Alzheimer’s disease, the Washington Post reported earlier this month. The AAD position statement on Sexual and Gender Minority Health in Dermatology says that, “Dermatologists can and should cTips to Increase Activity on your Dermatology Practice Facebook Page
https://practicaldermatology.com/topics/practice-management/tips-to-increase-activity-on-your-dermatology-prac/19602/Engaging with the Facebook users is essential to grow the business of your dermatology practice. In this Ekwa Marketing video, we share a few tips to help you expand your outreach on Facebook and sustain the necessary activity and interest on your page.Skin Cancer Awareness, Epiduo Data, Impoyz Launch
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-skin-cancer-awareness-epiduo-data-impoyz-launch/18307/Data shed light on patents' attitudes towards kids' sunblock and new findings emerge on melanoma risks. FDA accepts BLA for cemiplimab for advanced SCC and approves Novartis' Tafinlar in combination with Mekinist for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutationsThe Aesthetic Revolution and the Rise of Cosmetic Dermatology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/watch-now-the-aesthetic-revolution-and-the-rise-of-cosmetic-dermatology/18350/No doubt the practice of dermatology has been shaped by the emergence of minimally invasive aesthetic interventions. This second of four episodes exploring the history of dermatology takes a look at the evolution of cosmetic dermatology.Advances in Treating NMSC
https://practicaldermatology.com/topics/skin-cancer-photoprotection/advances-in-treating-nmsc/18742/Dr. Goldenberg discusses the benefits of timed sequential therapy using two modalities — destructive therapy followed by field therapy — for actinic keratoses. He also talks about treatment options for advanced basal cell carcinoma, squamous cell carcinoma, and merkel cell carcinoma.Cellfina Cleared, Finacea Foam Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-cellfina-cleared-finacea-foam-approved/18866/The FDA has cleared Cellfina (Ulthera Inc./Merz Aesthetics, Inc.) to treat cellulite, with results lasting for up to 2 years. Finacea Foam (azelaic acid, Bayer Dermatology) is approved for Rosacea, and Almirall invests in Suneva Medical, maker of Bellafill. Also in this edition, a look at the data o